ASCO Special: Dr. Rebecca Feldman Spills the Tea on Bispecifics, Biomarkers & Precision Oncology

In this special episode of HITea, we're live from ASCO, the world’s largest oncology conference, and thrilled to be joined by Dr. Rebecca Feldman, VP of Biomarker and Drug Intelligence at Caris Life Sciences. Dr. Feldman is a powerhouse at the intersection of precision medicine and data-driven oncology, and today, she shares her journey, insights from ASCO, and how Caris is revolutionizing the way we understand and treat cancer.

In this episode, we dive into:

Dr. Feldman’s path to becoming a leader in biomarker and drug intelligence

The hottest trends in precision oncology and how they’re shaping the future

Game-changing studies at ASCO, including new targets like CLDN18

How molecular profiling is unlocking treatments for rare and hard-to-treat cancers

The rise of advanced therapies like bispecifics, ADCs, and smart drug combinations

The role of AI and blood-based diagnostics (ctDNA) in transforming clinical trials

How Caris is helping to expand trial access to underserved populations, including kids and patients with rare mutations

Plus, we get personal: Dr. Feldman shares what drives her, how she overcomes challenges, and her advice to women navigating careers in healthcare and health IT.

This episode is for anyone curious about where oncology is headed and how technology is helping to lead the way—with empathy, intelligence, and precision.